{"entity":{"id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","aka":[],"tldr":"A phase 3 trial testing LM-108 in gastric & gastro-oesophageal junction cancer, now recruiting.","summary":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma is a phase 3 interventional study registered as NCT07362186, led by LaNova Medicines, and recruiting on the registry. Official title: A Phase III, Open-Label, Multicenter, Randomised, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Planned enrolment is 400 participants (estimated). The study started in 2026-04-30 and primary completion is expected in 2028-08-17. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07362186","url":"https://clinicaltrials.gov/study/NCT07362186"}],"tags":["ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["lm-108"],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07362186","phase":"3","setting":"A Phase III, Open-Label, Multicenter, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma","sponsor":"LaNova Medicines","participation":[{"nct":"NCT07362186","source":"https://clinicaltrials.gov/study/NCT07362186","fetchedAt":"2026-10-07T16:55:42.201Z","studySha256":"533ed5158744cc1f5bd96d69b8019e79da9d92fd84a46647ab1e442b04cae723","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-11","leadSponsor":"LaNova Medicines Limited","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":400,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-04-30","startedType":"actual","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07362186/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}